Advertisement

Business Briefing / PHARMACEUTICALS

FDA concerned about bone drug

September 05, 2008|From Times Wire Services

Federal regulators say a drug from Pfizer Inc. and Ligand Pharmaceuticals Inc. effectively treats osteoporosis, but they are concerned about deaths, blood clots and other problems seen in company studies.

The Food and Drug Administration noted that women treated with Pfizer's Fablyn were more likely to die of cancer or stroke than those taking a placebo. The FDA posted its review of the drug online in advance of a meeting Monday with outside advisors.

Advertisement
Los Angeles Times Articles
|
|
|